The use of fertility drugs that may cause alterations in endogenous hormones and multiple ovulations has raised concerns about the long-term safety of such medications. One concern is that are invasive ovarian cancer. Is this concern evidence-based? In this session, we will review the ASRM Practice Guideline on the subject (2016), as well as a more recent updated ASCO/ESHRE review from 2018.
